Antineoplastic Agents

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73

3 days ago talkbio0Tagged Antineoplastic Agents, AstraZeneca, Inhibitor, Jacobio Pharma, milestones, pan-KRAS

AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones

German Court Blocks Merck’s Subcutaneous Keytruda Over Patent Dispute with Halozyme

2 weeks ago talkbio0Tagged Antineoplastic Agents, Germany, Halozyme, Keytruda SC, Legal patent, MDASE, Merck, Munich Regional Court, Patent infringement, preliminary injunction, subcutaneous formulation

Merck; Keytruda SC; Halozyme; Germany; patent infringement; preliminary injunction; Munich Regional Court; subcutaneous formulation; cancer drug; MDASE patents

Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application

5 months ago talkbio0Tagged Antineoplastic Agents, Clinical Trial Design, Complete, Drops - Drug Form, Frequency of Responses, melanoma, Prices, Rejection, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration

Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop

Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS

6 months ago talkbio0Tagged AbbVie, Antineoplastic Agents, azacitidine, Clinical Research, Clinical Trials, Miller Dieker syndrome, MYELODYSPLASTIC SYNDROME, Phase 3 trial, Roche (company), Venclexta, venetoclax, Verona

Roche; AbbVie; Venclexta; venetoclax; azacitidine; myelodysplastic syndromes; MDS; Phase 3 trial; VERONA study; clinical trial results; cancer drug

Patent Dispute Erupts Over Merck’s Injectable Keytruda

10 months ago talkbio0Tagged Antineoplastic Agents, enzyme technology, Halozyme, Injectables, Keytruda, Legal patent, Merck

Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology

FDA Issues Untitled Letter to NJ Drugmaker for Misleading Cancer Drug Claims at Conference

10 months ago10 months ago talkbio0Tagged Antineoplastic Agents, booth, Edenbridge, Letter [Publication Type], Promotion (action), United States Food and Drug Administration

FDA, untitled letter, misleading promotion, exhibit booth, cancer drug, Edenbridge Pharmaceuticals

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts

11 months ago talkbio0Tagged Antineoplastic Agents, Appointments, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Novartis, Pfizer

Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment

Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs

1 year ago talkbio0Tagged Agenus, Antineoplastic Agents, BOT/BAL, botensilimab/balstilimab, Financial cost, layoffs, strategic realignment

Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development

FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials

1 year ago talkbio0Tagged Anemia, Antineoplastic Agents, Astellas, AstraZeneca, FibroGen, Neoplasms, pamrevlumab, Pancreatic carcinoma, Pharmacotherapy, Phase 3 Clinical Trials, roxadustat

FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca

Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo

1 year ago talkbio0Tagged Accelerated, Agenus, Antineoplastic Agents, Approved, BOT, BOT/BAL, Colorectal Carcinoma, stock selloff, United States Food and Drug Administration

Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff